<DOC>
	<DOCNO>NCT02334553</DOCNO>
	<brief_summary>Evaluate safety tolerability single dose S-1226 ( 8 % ) subject mild atopic asthma .</brief_summary>
	<brief_title>Single Dose Study Evaluate Safety , Efficacy S-1226 ( 8 % ) Subjects With Mild Atopic Asthma</brief_title>
	<detailed_description>Phase IIa , placebo-controlled , randomize , double-blind , crossover single dose study evaluate safety , tolerability efficacy S-1226 ( 8 % ) administer nebulization subject mild atopic asthma</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<criteria>1 . Male female subject 1840 year age . 2 . BMI 1840 kg/m2 3 . Subject currently topical systemic corticosteroid take oral/injectable corticosteroid within 60 day prior study drug administration use inhaled/nasal corticosteroid within 30 day prior study drug administration . 4 . Female subject must pregnant lactating must practice acceptable method birth control , surgically sterile postmenopausal . 5 . Subjects must asthma least 3 month . 6 . Subject nonsmoker smoke &gt; 1year &lt; 10 packyear history . 7 . Subject methacholine PC20 le 16mg/mL . 8 . Subject normal laboratory value ( normal value clinically judge Investigator ) clinical chemistry , hematology , urinalysis . 9 . Subject general good health base medical history clinically acceptable result follow assessment : physical examination , vital sign , 12lead ECG , assess study physician . 10 . Subject able communicate effectively study personnel reliable , willing cooperative term compliance protocol . Subjects follow applies exclude study : 1 . Any clinically significant abnormality abnormal laboratory test result find medical screening positive test hepatitis B , hepatitis C , HIV find medical screening . 2 . Subjects require inhaled β2agonist medication frequently 4 time week ( prophylactically prior exercise ) 4 week period screening . 3 . Subjects currently treat asthma medication inhale β2agonist . 4 . Subjects frequent emergency room visit asthma , prior ICU admission prior intubation . 5 . Presence history neurologic , endocrine , hepatic , gastrointestinal kidney disease therapy would jeopardize subject 's wellbeing participating study . 6 . Cardiovascular disease , opinion Investigator , stable could put subject increase risk participate study . 7 . Any reason , opinion Investigator ( delegate ) , would prevent subject participate study . 8 . Clinically significant electrocardiogram ( ECG ) abnormalities vital sign abnormality ( systolic blood pressure low 90 140 mmHg , diastolic blood pressure low 50 90 mmHg , heart rate less 50 100 bpm ) screening . 9 . Subject history physician diagnose panic disorder anxiety disorder . 10 . Subject currently receive treatment , receive treatment previous 14 day , monoamine oxidase ( MAO ) inhibitor . 11 . Subjects dose investigational drug within 30 day prior Screening Visit . 12 . Subjects dose biologic therapy within previous 4 month 5 halflives baseline methacholine test . 13 . Subject current ( within last six month ) evidence alcohol abuse ( regularly drink 4 unit alcohol per day ; 1 unit = ½ pint beer , 1 glass wine , 1 ounce spirit ) 14 . Positive urine drug screen urine cotinine test screening . 15 . Breastfeeding subject . 16 . Positive pregnancy test screening . 17 . Subject , opinion Investigator , mentally emotionally unsuitable participate , unable/unwilling comply study assessment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>COPD</keyword>
	<keyword>Chronic bronchitis</keyword>
	<keyword>Cystic fibrosis</keyword>
	<keyword>Bronchoconstriction</keyword>
	<keyword>Perfluorocarbons</keyword>
	<keyword>Carbon dioxide</keyword>
</DOC>